Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

14-12-2020 | SABCS 2020 | Conference coverage | Video

Adjuvant chemotherapy omission feasible for certain postmenopausal breast cancer patients

Kevin Kalinsky presents the SWOG S1007 RxPONDER trial suggesting that menopausal status could help guide adjuvant chemotherapy use in women with early-stage, HR-positive breast cancer and a low genomic recurrence score (5:15).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript
Image Credits